source
- BMS's Cobenfy faces market hurdles as side effects limit uptake, MapLight eyes opportunityThe FDA approved Bristol Myers Squibb's Cobenfy in 2024, marking the first novel schizophrenia treatment in 35 years and raising hopes for a new therapeutic approach. Since its launch, the drug ha…
- Latigo and BlossomHill file Nasdaq IPO plans to fund pain and cancer pipelinesLatigo Biotherapeutics and BlossomHill Therapeutics, both based in California, have filed applications to list on the Nasdaq Global Select Market. Latigo aims to raise up to $285.2 million to advan…